#ICANs - Twitter Hashtag

3 months ago

Insightful talk by @charlesrudin on T-cell engagers in #SCLC at #RomeLung26. Multiple agents are moving forward across settings and combinations, with #CRS, #ICANS, and lack of predictive biomarkers remaining key challenges. @OncoAlert @DanaFarberNews

BRicciutiMD's tweet photo. Insightful talk by @charlesrudin on T-cell engagers in #SCLC at #RomeLung26. Multiple agents are moving forward across settings and combinations, with #CRS, #ICANS, and lack of predictive biomarkers remaining key challenges. @OncoAlert @DanaFarberNews https://t.co/oNN3qEpxK1

1

18

4

0

1K

Hemostasis Today

@HemostasisToday

7 months ago

50% of Patients With Severe ICANS Develop Thrombosis – Here’s What’s Happening - Dr @abdulmannan74 https://t.co/aZeCqhMxz0 #Coagulopathy #Hemostasis #HemostasisNews #HemostasisToday #ICANS #Thrombosis #MedEd #MedX

HemostasisToday's tweet photo. 50% of Patients With Severe ICANS Develop Thrombosis – Here’s What’s Happening - Dr @abdulmannan74

https://t.co/aZeCqhMxz0

#Coagulopathy #Hemostasis #HemostasisNews #HemostasisToday #ICANS #Thrombosis #MedEd #MedX https://t.co/iQy58lDAiE

0

4

1

37

Neurology Journal @GreenJournal

9 months ago

Neurology Podcast: Dr. Alison Christy and Dr. Jennifer McGuire discuss neuroimaging findings linked to #ICANS, exploring whether specific imaging patterns correlate with distinct neurologic symptoms. Listen now: https://t.co/mH9SNtkGib #NeuroTwitter #NeuroX

1

15

4

2

2K

Journal of Neuroimmunology (JNI) @JNI_Journal

11 months ago

CAR-T therapy is revolutionising cancer care, but ICANS & new neurotoxicities remain major hurdles - biomarkers & targeted treatments are urgently needed. #CART #Oncology #Neurotoxicity #ICANS Check out the paper below 👇 https://t.co/j8BSF9m3d2

0

3

1

0

184

Andreu Vilaseca

@andreuvilaseca7

12 months ago

Could #ICANS after antiCD19 CAR-T be less “benign” than we thought? In a case-control study from the @VHIO CAR-T cohort, patients with more severe ICANS (≥grade2) showed signs of neuroaxonal damage during the episode! 💡Could prevention or earlier treatment change the story?

andreuvilaseca7's tweet photo. Could #ICANS after antiCD19 CAR-T be less “benign” than we thought?
In a case-control study from the @VHIO CAR-T cohort, patients with more severe ICANS (≥grade2) showed signs of neuroaxonal damage during the episode!
💡Could prevention or earlier treatment change the story? https://t.co/VuVZs7kcZy

0

7

1

440

Associate Professor Mastura Monif @MasturaMonif

about 1 year ago

Hot off the press today, check out our super talented PhD student, Christina Kazzi's paper: How a simple clock drawing test can complement current #ICANS assessment in #CART patients. Well done Christina! 👏 @MonashSTM @AlfredHealth CART program. https://t.co/sYpBQlhmay

0

3

0

158

Sara G. Gil-Perotin @GilPerotin

about 1 year ago

Great news! Our collaborative work led by Marina Gomez-Gobell is out — exploring serum and CSF cytokine profiling in CAR-T–related neurotoxicity. Now published in Bone Marrow Transplantation. #CART #Neurotoxicity #ICANS 🔗 https://t.co/9kilanS2vJ

1

3

1

0

128

Marina Gómez-Llobell @GomezLlobell

about 1 year ago

New in @BMTjournal ICANS risk models after CD19 #CARTcell therapy using cytokines (IL-6, IL-15, GM-CSF) + CSF 🧠🧪 Grateful to my mentors at @HematoHGUGM and our amazing team 🧠💊 and collaborators 🔗 https://t.co/gz5LXFLEio #ICANS #Neurotoxicity #Immunotherapy

0

2

0

30

Andrew Smith @AndrewSmith_AI

about 1 year ago

Pediatric Blood & Cancer journal published this fascinating study by @SoniyaNaomiMbbs of an atypical presentation of recurrent ICANS after tisagenlecleucel therapy following a previous resolution. Read more about it here: https://t.co/8eOczuBDJL @StJudeResearch #ICANS #CAR-T

AndrewSmith_AI's tweet photo. Pediatric Blood & Cancer journal published this fascinating study by @SoniyaNaomiMbbs of an atypical presentation of recurrent ICANS after tisagenlecleucel therapy following a previous resolution.
Read more about it here: https://t.co/8eOczuBDJL @StJudeResearch #ICANS #CAR-T https://t.co/wtHhQJIUi1

0

3

1

0

172

Anuja Abhyankar @anuja_abhyankar

about 1 year ago

Please check out this short video where I share insights about our research at Roswell Park regarding the use of prophylactic steroids in patients at a high risk of CRS and ICANS and its effect on outcomes. #CART #ASCO25 #CRS #ICANS

Shernan Holtan MD

@sghmd

about 1 year ago

ASCO® 2025 Insights: Effect of Prophylactic Corticosteroids on Toxicities & Outcomes in CAR T-Cell Therapy - A Cohort Study | VuMedi https://t.co/ciWCpHGES0 via @vumedi

0

12

2

6

3K

2

20

2

0

2K

Alex Detappe @AlxDetappe

about 1 year ago

Huge thanks to our funding agencies - #SNSF, @ERC_Research @Liguecancer67, #IMSstrasbourg, and generous donors to #ICANS. Special thanks to all collaborators from @unistra, @Inserm @GoetzJacky Céline Mirjolet and team members

1

3

0

143

Aakash Desai, MD, MPH, FASCO @ADesaiMD

about 1 year ago

Results from #DeLLphi304 Phase 3 trial in @NEJM #Tarlatamab vs Chemotherapy as 2L for advanced #SmallCell #LungCancer 🫁 ✅ mOS: 13.6 vs 8.3 months (HR 0.60) ✅ Grade ≥3 AEs: 54% vs 80% ✅ #CRS & #ICANS mostly grade 1/2 ‼️ This is practice changing and practice confirming (if you were using this 2L!) @ASCO #ASCO25

Rami Manochakian MD, FASCO Cancer Education

@RManochakian

about 1 year ago

🔥🚨@OncoAlert Hot Off The Press Just published @NEJM in conjunction with presentation @ASCO #ASCO25 Results of #DeLLphi304 phase trial of: #Tarlatamab vs #Chemotherapy in 2nd Tx for advanced #SmallCell #LungCancer ✅#mOS: 13.6 vs 8.3 months (HR: 0.6) ✅More Improvement in symptoms with #Tarlatamab ✅ ≥ Grade 3 AEs: 54% vs 80% ✅#CRS & #ICANS mostly grade 1/2 👇🏻 https://t.co/d27PERgpsM

RManochakian's tweet photo. 🔥🚨@OncoAlert Hot Off The Press

Just published @NEJM in conjunction with presentation @ASCO #ASCO25

Results of #DeLLphi304 phase trial of:
#Tarlatamab vs #Chemotherapy in 2nd Tx for advanced #SmallCell #LungCancer

✅#mOS: 13.6 vs 8.3 months (HR: 0.6)
✅More Improvement in symptoms with #Tarlatamab
✅ ≥ Grade 3 AEs: 54% vs 80%
✅#CRS & #ICANS mostly grade 1/2

👇🏻
https://t.co/d27PERgpsM

3

75

29

13

16K

1

20

10

2

2K

Alessio Cortellini @ACortelliniMD

about 1 year ago · Chicago

Amazing talk by @thenasheffect in a packed Arie Crown Theater at #ASCO2025 on dll3/cd3 bispecifics, how #CRS and #ICANS can cluster and on potential biomarkers for neurotox! The bar has been raised and we need to learn how to deal with new tox @ASCO

ACortelliniMD's tweet photo. Amazing talk by @thenasheffect in a packed Arie Crown Theater at #ASCO2025 on dll3/cd3 bispecifics, how #CRS and #ICANS can cluster and on potential biomarkers for neurotox!
The bar has been raised and we need to learn how to deal with new tox @ASCO https://t.co/qvIEOWtfcI

0

18

7

1

939

OncLive.com

@OncLive

over 1 year ago

Real-world data showed that #CRS occurred in 95% (n = 42) of patients with B-cell malignancies, all of which were characterized as grade 1 or 2 events, and #ICANS occurred in 9% (n = 4) of patients and was grade 1/2 in 1% of cases and grade 3/4 in 3%. https://t.co/mCzTTP2o2s

OncLive's tweet photo. Real-world data showed that #CRS occurred in 95% (n = 42) of patients with B-cell malignancies, all of which were characterized as grade 1 or 2 events, and #ICANS occurred in 9% (n = 4) of patients and was grade 1/2 in 1% of cases and grade 3/4 in 3%.
https://t.co/mCzTTP2o2s https://t.co/SH1YF1d3PC

0

2

0

1

627

Guillaume @Guillau13441190

over 1 year ago

Encéphalite induite par l'immunotherapie et/ou la chimiothérapie. Publication suisse de 2024. Desbaillets NP, Hottinger AF. Cancer Therapy-Induced Encephalitis. #Cancer #Neurotoxicity #encephalitis #autoimmunedisease, #immunotherapy #ICANS https://t.co/cjVumCzCgp

3

7

0

280

Hidehito HORINOUCHI

@HHorinouchi

over 1 year ago

🔥 @ClinicalLung 🆙 ✅Real-World Outcomes of Tarlatamab in SCLC 🎯Special considerations are required for pts with brain mets due to the increased risk of severe #ICANS 👥 Dr. Fabian J. Bolte #LCSM @OncoAlert https://t.co/qfnIM4lulU

1

23

8

11

2K

Hematologia ICO Hospitalet @HematICO_Hosp

over 1 year ago

Our #ICOnic Neurology Team is also present at #EBMT25 Congratulations @VelascoRoser for this publication! We are so lucky to have you on board! #NeuroHemato #CNS #ICANS

Felipe Peña-Muñoz @HematoRules

over 1 year ago

🚨 Just presented at #EBMT25 and Just released at @TheLancetOncol 🚨 Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee Amazing job @VelascoRoser et al! @TheEBMT @TheEBMT_Trainee

HematoRules's tweet photo. 🚨 Just presented at #EBMT25 and Just released at @TheLancetOncol 🚨

Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee

Amazing job @VelascoRoser et al!
@TheEBMT @TheEBMT_Trainee https://t.co/YwvAfIfYnX

0

53

11

32

4K

0

4

0

1

302

Transplantation and Cellular Therapy Journal @ASTCT_Journal

over 1 year ago

High-dose anakinra (up to 12 mg/kg/day) is a safe option for refractory #CRS and #ICANS after CAR T therapy. This study suggests higher doses may speed resolution and reduce treatment-related mortality. Read the full article: https://t.co/gHPLAUoHUA

$ASTCT_Journal's tweet photo. High-dose anakinra (up to 12 mg/kg/day) is a safe option for refractory #CRS and #ICANS after CAR T therapy. This study suggests higher doses may speed resolution and reduce treatment-related mortality. Read the full article: https://t.co/gHPLAUoHUA https://t.co/2V2i91l0LU$

0

36

16

25

2K

Alex Detappe @AlxDetappe

over 1 year ago

Our latest in @nanoscale_rsc shows how optimizing ligand accessibility on iron oxide NPs boosts tumor antigen recognition, binding & penetration, improving EGFR-targeted photothermal therapy - @ERC_Research @laliguecancer #ICANS @SBeginColin @HarleppS

Nanoscale journal family @nanoscale_rsc

over 1 year ago

Enhancing ligand accessibility on nanoparticle surfaces improves tumour antigen recognition, binding, and penetration — a proof-of-concept with IONPs targeting EGFR for enhanced photothermal therapy. @AlxDetappe @HarleppS @SBeginColin Read more here: https://t.co/oBZStIwaxA

nanoscale_rsc's tweet photo. Enhancing ligand accessibility on nanoparticle surfaces improves tumour antigen recognition, binding, and penetration — a proof-of-concept with IONPs targeting EGFR for enhanced photothermal therapy.

@AlxDetappe @HarleppS @SBeginColin

Read more here:
https://t.co/oBZStIwaxA https://t.co/LZczJE1Xft

0

3

0

602

0

2

0

376

Gabriel Malouf @GabrielMalouf

over 1 year ago

Excited to share results from our French national UroCCR network regarding racial disparities in RCC, with black patients showing highly likelihood for presenting rare variants of RCC. Thanks for @uroccr collaborators and team #CARARE #icans @kidneycan @kcCURE @BigotP

OncLive.com

@OncLive

over 1 year ago

Racial Disparities in RCC: Insights from France! Xiaofan Lu, PhD, @uroccr Unlike U.S. data, race was not an independent prognostic factor, suggesting healthcare system impact. #GU25 @asco @DrYukselUrun #cancer #oncology @DrChoueiri @yekeduz_emre @CParkMD @AlbigesL

OncLive's tweet photo. Racial Disparities in RCC: Insights from France!
Xiaofan Lu, PhD, @uroccr
Unlike U.S. data, race was not an independent prognostic factor, suggesting healthcare system impact.
#GU25 @asco @DrYukselUrun #cancer #oncology @DrChoueiri @yekeduz_emre @CParkMD @AlbigesL https://t.co/VfPwPt0B0F

1

19

6

1

3K

2

18

6

0

3K

Top Tweets for #ICANs

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users